Home > Publications database > Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas > print

001     1006427
005     20231027114400.0
024 7 _ |a 10.3390/molecules28072890
|2 doi
024 7 _ |a 2128/34582
|2 Handle
024 7 _ |a 37049661
|2 pmid
024 7 _ |a WOS:001001567200001
|2 WOS
037 _ _ |a FZJ-2023-01662
082 _ _ |a 540
100 1 _ |a Neumaier, Felix
|0 P:(DE-Juel1)175142
|b 0
245 _ _ |a Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
260 _ _ |a Basel
|c 2023
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687840183_8046
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a This work was supported by Deutsche Forschungsgemeinschaft (DFG), grant number NE 890/9-1.
520 _ _ |a Gliomas are the most common primary brain tumors in adults. A diffuse infiltrativegrowth pattern and high resistance to therapy make them largely incurable, but there are significantdifferences in the prognosis of patients with different subtypes of glioma. Mutations in isocitratedehydrogenase (IDH) have been recognized as an important biomarker for glioma classification anda potential therapeutic target. However, current clinical methods for detecting mutated IDH (mIDH)require invasive tissue sampling and cannot be used for follow-up examinations or longitudinalstudies. PET imaging could be a promising approach for non-invasive assessment of the IDH statusin gliomas, owing to the availability of various mIDH-selective inhibitors as potential leads for thedevelopment of PET tracers. In the present review, we summarize the rationale for the developmentof mIDH-selective PET probes, describe their potential applications beyond the assessment of theIDH status and highlight potential challenges that may complicate tracer development. In addition,we compile the major chemical classes of mIDH-selective inhibitors that have been described to dateand briefly consider possible strategies for radiolabeling of the most promising candidates. Whereavailable, we also summarize previous studies with radiolabeled analogs of mIDH inhibitors andassess their suitability for PET imaging in gliomas.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Zlatopolskiy, Boris D.
|0 P:(DE-Juel1)176188
|b 1
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 2
|e Corresponding author
773 _ _ |a 10.3390/molecules28072890
|g Vol. 28, no. 7, p. 2890 -
|0 PERI:(DE-600)2008644-1
|n 7
|p 2890
|t Molecules
|v 28
|y 2023
|x 1420-3049
856 4 _ |u https://juser.fz-juelich.de/record/1006427/files/molecules-28-02890-1.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1006427
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)175142
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)166419
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
914 1 _ |y 2023
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a DOAJ Journal
|0 PC:(DE-HGF)0003
|2 APC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-23
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-23
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-23
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:17Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:01:17Z
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOLECULES : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-10-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-22
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a APC
980 1 _ |a APC
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21